Tango Therapeutics (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$26.64
-$0.22(-6.34%)
At close: 4:00 PM EST
$26.64
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$1.03 - $28.41
Previous CloseN/A
Volume187.94K
Average Volume (3M)3.04M
Market Cap
$3.76B
Enterprise Value$2.84B
Total Cash (Recent Filing)$343.14M
Total Debt (Recent Filing)$33.57M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding142,688,860
10 Day Avg. Volume3,795,201
30 Day Avg. Volume3,037,748
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue45.55
Enterprise Value/Gross Profit46.80
Enterprise Value/Ebitda-27.05
Forecast
1Y Price Target
$25.29Price Target Upside-5.08% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$6.66M
Bulls Say, Bears Say
Bulls Say
Clinical Program MomentumRobust enrollment and favorable safety observations in the vopimetostat combination study, together with leading monotherapy clinical data and multiple external collaborations, position the company to be among the first to show proof‑of‑concept results and gain competitive advantage in pancreatic cancer.
Clinical ReadoutsDaraxonrasib's large survival benefit over chemotherapy raises the likelihood that combining the drug with Tango's PRMT5 inhibitor vopimetostat will improve outcomes for patients with MTAP‑deleted pancreatic cancer and support adoption as a new treatment option.
Partnerships And Preclinical DataA collaboration to test a partner's pan‑RAS molecular glue that demonstrated stronger target binding and superior tumor control in preclinical models increases the odds the combination will be clinically potent and attract further partner interest.
Bears Say
Execution RiskDependence on positive outcomes from planned clinical readouts creates execution risk that could depress the stock if trials fail to meet endpoints or encounter delays.
Regulatory UncertaintyMeaningful regulatory uncertainty for vopimetostat elevates approval risk, which may limit upside even if clinical data are encouraging.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $1.03 and its highest was $28.41 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $3.76B.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 13 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Mar 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.028.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Overvalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 142,688,860 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 36.275%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.29 (-5.08% Downside)
$25.29 (-5.08% Downside)
Hedge Fund Trend
Increased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $968.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.97%
12-Months-Change
Fundamentals
Return on Equity
-50.30%
Trailing 12-Months
Asset Growth
24.64%
Trailing 12-Months
Company Description
Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$25.29
▼(-5.08% Downside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
11.05% Insiders
8.19% Mutual Funds
0.36% Other Institutional Investors
69.39% Public Companies and
Individual Investors